GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...

Low vitamin D in patients with nasal polyps negatively correlated with several markers, including Lund-Mackay and total nasal polyp scores. “Recently, the role of vitamin D in the development of ...

This could potentially transform treatment paradigms by reducing the ... effectively reduced the size and obstruction of nasal polyps compared to placebo. Kaivan Khavandi, SVP, Global Head of ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

The inclusion criteria for patients were: (a) met the diagnostic criteria of the “European Position Paper on Rhinosinusitis and Nasal Polyps 2020”; (b) aged ≥18 years; (c) no relevant medication ...

Nasal microbiota transplantation could revolutionise the treatment of chronic rhinosinusitis and respiratory tract infections ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...